Prosecution Insights
Last updated: November 04, 2026
Application No. 18/682,919

AMORPHOUS CALCIUM PHOSPHATE CERAMIC-BASED DRUG DELIVERY SYSTEM AND METHOD FOR ITS FABRICATION

Final Rejection §103
Filed
Feb 11, 2024
Priority
Aug 10, 2021 — LA LVP2021000045 +1 more
Examiner
OLSON, ANDREA STEFFEL
Art Unit
1693
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Rigas Tehniska Universitate
OA Round
2 (Final)
62%
Grant Probability
Moderate
3-4
OA Rounds
5m
Est. Remaining
51%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allowance Rate
894 granted / 1431 resolved
+2.5% vs TC avg
Minimal -12% lift
Without
With
+-11.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
59 currently pending
Career history
1503
Total Applications
across all art units

Statute-Specific Performance

§101
3.1%
-36.9% vs TC avg
§103
37.5%
-2.5% vs TC avg
§102
17.5%
-22.5% vs TC avg
§112
23.0%
-17.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1431 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Detailed Action This office action is a response to applicant’s communication submitted September 9, 2026, wherein claims 1-6 are amended and new claim 7 is introduced. This application is a national stage application of PCT/IB2022/056873, filed July 26, 2022, which claims benefit of foreign application P2021000045, filed August 10, 2026. Claims 1-7 are pending in this application. Claims 1-7 as amended are examined on the merits herein. Withdrawn Rejections Applicant’s amendment, submitted September 9, 2026, with respect to the rejection of claims 4-6 under 35 USC 112(d) for failing to include all of the limitations of base claim 1, has been fully considered and found to be persuasive to remove the rejection as claims 4-6 have been amended to claim a method as recited in claim 1. Therefore the rejection is withdrawn. Applicant’s amendment, submitted September 9, 2026, with respect to the rejection of claims 4-6 under 35 USC 103 for being obvious over Rubenis et al. in view of Epple et al., has been fully considered and found to be persuasive to remove the rejection as the claims have been amended to be directed to processes requiring the specific high pressure treatment recited in claim 1. Therefore the rejection is withdrawn. The following rejections of record in the previous action are maintained and applied to the claims as presently amended: Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-7 are rejected under 35 U.S.C. 103 as being unpatentable over Rubenis et al. (Non-patent literature 1 included with 1/23/2025 PTO-1449) in view of Epple et al. (Foreign document EP1520593, Foreign reference 1 included with 1/23/2025 PTO-1449) and further in view of Swain et al. (Reference included with 5/12/2026 PTO-892) Claim 1 is directed to a method for fabrication of an amorphous calcium phosphate drug delivery system comprising sintering a mixture of amorphous calcium phosphate and a drug at a temperature having a range encompassing room temperature and a pressure of greater than 600 MPa. Rubenis et al. discloses that ceramics made from amorphous calcium phosphate are of interest as artificial bone substitute materials but are difficult to produce as they tend to crystallize when heated during sintering. (p. 912 left column first and second paragraphs) Rubenis et al. further discloses a cold sintering process for formation of such ceramics wherein amorphous calcium phosphate is subjected to a pressure of 500 mPa at temperatures including room temperature. (p. 913 section 2.2) While the pressure used is not in excess of 600 mPa as recited in the method of claim 1, Rubenis et al. suggests that amorphous calcium phosphate could be further densified by room temperature sintering at pressures of greater than 500 MPa. (p. 918 section 4) Furthermore Swain discloses densification of a beta-tricalcium-phosphate using cold sintering. (p. 89 right column first paragraph) This process was carried out at pressures of 2.5 GPa. (p. 90 section 2.3) It would have been obvious to one of ordinary skill in the art at the time of the invention to carry out the densification process described by Rubenis at pressures higher than 600 MPa, for example any pressure up to 2.5 GPa. One of ordinary skill in the art would have found this to be obvious in view of the suggestion by Rubenis to use even higher pressures, and by Swain that pressures as high as 2.5 GPa are appropriate. Rubenis et al. does not disclose a composition further comprising gentamicin. However, Epple et al. discloses resorbable bone substitute materials comprising an active agent that is released from the material. (p. 3 paragraphs 30-32) This material can be prepared by cold-isostatic pressing. (p. 4 paragraph 33) In a particular embodiment (example 3 pp. 10-11) the active drug ingredient is gentamicin sulphate. It would have been obvious to one of ordinary skill in the art at the time of the invention to formulate amorphous calcium phosphate according to Rubenis et al. in combination with gentamicin sulfate. One of ordinary skill in the art would have seen the disclosure of Epple et al. as suggesting that similar bone substitute materials can be advantageously loaded with this active agent. Regarding dependent claim 2, this claim merely requires that the amorphous calcium phosphate be stabilized, without indicating what counts as stabilization. Swain et al. (see bottom of right column of p. 88 right column first paragraph of p. 89) discloses the addition of other components such as polymers or metals to increase the strength of the ceramic. Such a material, whose production is suggested by the prior art, would reasonably be considered to be stabilized. Regarding dependent claim 3, Epple et al. discloses an embodiment wherein the material contains about 0.25g gentamicin sulfate to 5g calcium phosphate, for a ratio of about 1:0.05. (pp. 10-11 paragraph 128) Regarding claims 5-6, the intended use limitations recited in these claims are not seen to impart any further structural limitations that would differentiate the claimed substances from the prior art calcium phosphate compositions. Regarding claim 7, it would have been obvious to one of ordinary skill in the art at the time of the invention to determine an appropriate cold sintering pressure of above 600 MPa such as 1500 MPa. One of ordinary skill in the art would have seen pressure values within this range to be obvious in view of the suggestion by the prior art to try higher pressures. Therefore the invention taken as a whole is prima facie obvious. Response to Arguments: Applicant’s arguments, submitted September 9, 2026, with respect to the above grounds of rejection, have been fully considered and not found to be persuasive to remove the rejection. Applicant’s arguments are based on two lines of reasoning, firstly that the suggestion to use pressures above 500 MPa is not the same as suggesting pressures above 600 MPa, and secondly that Swain discloses a cold sintering process for a different material, which is a nanocrystalline carbonated apatite. However, looking to the relevant considerations, the present rejection can be seen as being a question of the obviousness of a claimed range (greater than 600 MPa) over a broader range encompassing the claimed range. (Greater than 500 MPa) According to MPEP 2144.05, when the claimed range overlaps or lies inside of a prior art range, a prima facie case of obviousness exists, and "[A] prior art reference that discloses a range encompassing a somewhat narrower claimed range is sufficient to establish a prima facie case of obviousness." Furthermore, the statement by Rubenis et al. suggests increasing the pressure above 500 MPa as an avenue for further research. Regarding the differences between the claimed material and that described by Swain, while it is true that Swain does not describe the exact same starting material described by Rubenis et al. and the present claims, the motivation for increasing the pressure above the prior art value of 500 MPa comes from Rubenis. The disclosure of Swain is relied upon merely to show that higher pressures above 600 MPa are possible. The rejection does not depend on this reference to teach the exact same starting material. For these reasons the rejections are deemed proper and maintained. Conclusion No claims are allowed in this action. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANDREA OLSON whose telephone number is (571)272-9051. The examiner can normally be reached M-F 6am-3:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Y Goon can be reached at 571-270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ANDREA OLSON/ Primary Examiner, Art Unit 1693 10/19/2026
Read full office action

Prosecution Timeline

Feb 11, 2024
Application Filed
May 12, 2026
Non-Final Rejection mailed — §103
Sep 09, 2026
Response Filed
Oct 22, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780951
METHOD FOR PRODUCING CATIONIZED CELLULOSE AND CATIONIZED CELLULOSE
4y 5m to grant Granted Nov 03, 2026
Patent 12782341
METHOD FOR EXTRACTING AND IDENTIFYING POLYSACCHARIDE FROM COMPLEX SAMPLE
2y 11m to grant Granted Nov 03, 2026
Patent 12773420
CANCER CHEMOTHERAPY SUPPORTING AGENT, FOOD, AND DRUG
4y 8m to grant Granted Oct 27, 2026
Patent 12773680
LACTIC ACID ADSORBENT AND METHOD FOR REMOVING LACTIC ACID
4y 5m to grant Granted Oct 27, 2026
Patent 12758569
TREATMENT OF RNA VIRUS INFECTION WITH A CYTIDINE DEAMINASE INHIBITOR
3y 0m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
62%
Grant Probability
51%
With Interview (-11.9%)
3y 1m (~5m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1431 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month